Lund, Sweden, 11th April, 2017 – BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease or related surgery, announces the appointment of Michael Diefenbeck MD PhD as Chief Medical Officer.
Dr Diefenbeck founded Scientific Consulting in Orthopaedic Surgery in 2014 and has worked for BONESUPPORT on a range of clinical projects related to CERAMENT™ as an independent clinical advisor.
Company anticipates sharing topline data and completing regulatory submissions in 2018
GAITHERSBURG, Md., March 15, 2017 /PRNewswire/ -- Vtesse, Inc. announced today that its registrational study of investigational drug VTS-270 in Niemann-Pick Type C1 disease (NPC) is fully enrolled.
$51.7 million financing broadens investor base and provides flexibility to advance clinical stage potentiator program and expand antibacterial pipeline
CAMBRIDGE, Mass, March 8, 2017 – Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies to treat bacterial infections, announced today that it has completed a $51.7 million Series C preferred financing led by new investor GV (formerly Google Ventures). The round includes participation by additional new investors RA Capital Management and Rock Springs Capital as well as existing investors.
Cambridge, UK, February 20 2017 – VHsquared, the oral domain antibody company, is pleased to announce that the first patients have entered the international Phase II trial of its lead product, V565, in Crohn's disease. The aim of the HARBOR study1 is to show the efficacy of the anti-TNFα oral domain antibody as measured by changes in clinical symptoms, markers of inflammation and endoscopic appearance. It is randomised, doubleblind and placebo-controlled, involving over 100 patients with moderately to severely active Crohn’s disease. VHsquared is developing a portfolio of complementary oral domain antibodies (Vorabodies) which engage validated biological targets with the potential to transform the treatment of inflammatory bowel disease (IBD).
Extensive Phase 3 programme demonstrates clinical potential of BAREMSIS in rescue treatment and prophylaxis of PONV – NDA to be submitted to the US FDA 1H 2017
Cambridge, UK – 13th February 2017: Acacia Pharma Group Ltd (“Acacia Pharma”), the supportive care company developing products for US and international markets, announces positive results from its fourth and final pivotal Phase 3 study investigating BAREMSIS™ (amisulpride injection, formerly APD421) for the rescue treatment of patients who develop post-operative nausea & vomiting (PONV), despite having received prior antiemetic prophylaxis.
|1 2 3 4 5 6 7 8 9 10 Næste 10 Næste|